Press Release

BioOutsource expands ADC characterisation capabilities

BioOutsource expands ADC characterisation capabilities A global leader in ADC characterisation, BioOutsource, partners with Glythera. Exhibits at World ADC Summit in Frankfurt. GLASGOW, Scotland.  – 18 February 2014 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organization (CTO) has amplified its position as a global leader in Antibody Drug Conjugates (ADC) characterisation and are pleased to announce a partnership with Glythera Ltd, an emerging biotechnology company based in Newcastle-upon-Tyne that specializes in the development of next generation biotherapeutics through…

Read more>>

North East Based Biotechnology Firm Receives £700k Funding Boost

Investment will progress the development of a new generation of biological therapeutics through advanced glycosylation technologies. 8 July 2013, Newcastle-Upon-Tyne: Glythera Ltd is delighted to announce that it has successfully achieved a number of technical and commercial milestones which has resulted in the release of a second tranche of funding totalling £700k from IP Group and its managed fund, the Finance for Business North East Technology Fund. Glythera, a UK based spin out specialising in a new generation of biological…

Read more>>

Glythera relocates to North East as part of £2M funding round

Glythera, an emerging biopharmaceutical company specialising in protein/peptide functionalisation and glycosylation, has secured a fundraising round totalling £2M with IP Group, which will be tranched over the next three years. The company, a spin-out from the University of Bath, has recently established commercial operations at Newcastle's INEX incubator facility, following an initial £600,000 investment split equally between IP Group and its managed fund, the Finance for Business North East Technology Fund. The next two tranches will be of a similar…

Read more>>